{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:44:36Z","timestamp":1790228676343,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,2,9]],"date-time":"2012-02-09T00:00:00Z","timestamp":1328745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00228-012-1216-7","type":"journal-article","created":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T07:32:19Z","timestamp":1328686339000},"page":"1013-1018","source":"Crossref","is-referenced-by-count":85,"title":["Bisphosphonates: effects on osteoblast"],"prefix":"10.1007","volume":"68","author":[{"given":"Nicola","family":"Maruotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,9]]},"reference":[{"key":"1216_CR1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/ard.48.5.396","volume":"48","author":"SH Ralston","year":"1989","unstructured":"Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA (1989) Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 48:396\u2013399","journal-title":"Ann Rheum Dis"},{"key":"1216_CR2","first-page":"2016","volume":"21","author":"F Eggelmeijer","year":"1994","unstructured":"Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC (1994) Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 21:2016\u20132020","journal-title":"J Rheumatol"},{"key":"1216_CR3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1651-2227.2000.tb01214.x","volume":"89","author":"R Lala","year":"2000","unstructured":"Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C (2000) Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 89:188\u2013193","journal-title":"Acta Paediatr"},{"key":"1216_CR4","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508\u20131514","journal-title":"Science"},{"key":"1216_CR5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","volume":"382","author":"JM Lane","year":"2001","unstructured":"Lane JM, Khan SN, O\u2019Connor WJ et al (2001) Bisphosphonate therapy in fibrous dysplasia. Clin Orthop 382:6\u201312","journal-title":"Clin Orthop"},{"key":"1216_CR6","first-page":"711","volume":"4","author":"AA Reszka","year":"2004","unstructured":"Reszka AA, Rodan GA (2004) Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 4:711\u2013719","journal-title":"Mini Rev Med Chem"},{"key":"1216_CR7","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","volume":"12","author":"JC Frith","year":"1997","unstructured":"Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2019-(beta, gammadichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358\u20131367","journal-title":"J Bone Miner Res"},{"key":"1216_CR8","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E","volume":"44","author":"JC Frith","year":"2001","unstructured":"Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201\u20132210","journal-title":"Arthritis Rheum"},{"key":"1216_CR9","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643\u20132658","journal-title":"Curr Pharm Des"},{"key":"1216_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jbmr.5650050107","volume":"5","author":"M Sato","year":"1990","unstructured":"Sato M, Grasser W (1990) Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:31\u201339","journal-title":"J Bone Miner Res"},{"key":"1216_CR11","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato M, Grasser W, Endo N et al (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095\u20132105","journal-title":"J Clin Invest"},{"key":"1216_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S8756-3282(95)00150-6","volume":"17","author":"H Murakami","year":"1995","unstructured":"Murakami H, Takahashi N, Sasaki T et al (1995) A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137\u2013144","journal-title":"Bone"},{"key":"1216_CR13","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1172\/JCI118283","volume":"96","author":"Z Zimolo","year":"1995","unstructured":"Zimolo Z, Wesolowski G, Rodan GA (1995) Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 96:2277\u20132283","journal-title":"J Clin Invest"},{"key":"1216_CR14","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","volume":"97","author":"GA Rodan","year":"1996","unstructured":"Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692\u20132696","journal-title":"J Clin Invest"},{"key":"1216_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1254\/jjp.66.25","volume":"66","author":"M Tsuchimoto","year":"1994","unstructured":"Tsuchimoto M, Azuma Y, Higuchi O et al (1994) Alendronate modulates osteogenesis of human osteoblastic cell in vitro. Jpn J Pharmacol 66:25\u201333","journal-title":"Jpn J Pharmacol"},{"key":"1216_CR16","first-page":"S171","volume":"10","author":"N Giuliani","year":"1995","unstructured":"Giuliani N, Girasole G, Pedrazzoni M, Passeri G, Gatti C, Passeri M (1995) Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 10:S171","journal-title":"J Bone Miner Res"},{"key":"1216_CR17","first-page":"233","volume-title":"Methods in molecular medicine: human cell culture protocols","author":"JA Gallagher","year":"1998","unstructured":"Gallagher JA, Gundle R, Beresford JN (1998) Isolation and culture of bone-forming cells (osteoblasts) from human bone. In: Jones GE (ed) Methods in molecular medicine: human cell culture protocols. Humana, Totowa, pp 233\u2013262"},{"key":"1216_CR18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S8756-3282(98)00033-7","volume":"22","author":"N Giuliani","year":"1998","unstructured":"Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G (1998) Biphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455\u2013461","journal-title":"Bone"},{"key":"1216_CR19","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1359\/jbmr.2001.16.11.2050","volume":"16","author":"I Mathov","year":"2001","unstructured":"Mathov I, Plotkin LI, Sgarlata CL, Leoni J, Bellido T (2001) Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res 16:2050\u20132056","journal-title":"J Bone Miner Res"},{"key":"1216_CR20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","volume":"291","author":"V Viereck","year":"2002","unstructured":"Viereck V, Emons G, Lauck V et al (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680\u2013686","journal-title":"Biochem Biophys Res Commun"},{"key":"1216_CR21","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.biomaterials.2003.11.024","volume":"25","author":"G Im","year":"2004","unstructured":"Im G, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25:4105\u20134115","journal-title":"Biomaterials"},{"key":"1216_CR22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S1357-2725(03)00107-9","volume":"35","author":"EJ Mackie","year":"2003","unstructured":"Mackie EJ (2003) Osteoblasts: novel roles in orchestration of skeletal architecture. Int J Biochem Cell Biol 35:1301\u20131305","journal-title":"Int J Biochem Cell Biol"},{"key":"1216_CR23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0014-5793(98)01731-1","volume":"443","author":"HH Kim","year":"1999","unstructured":"Kim HH, Lee DE, Shin JN et al (1999) Receptor activator of NF-kB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 443:297\u2013302","journal-title":"FEBS Lett"},{"key":"1216_CR24","doi-asserted-by":"crossref","first-page":"31155","DOI":"10.1074\/jbc.M001229200","volume":"275","author":"M Matsumoto","year":"2000","unstructured":"Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kB ligand (RANKL). J Biol Chem 275:31155\u201331161","journal-title":"J Biol Chem"},{"key":"1216_CR25","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/emboj\/20.6.1271","volume":"20","author":"N Kobayashi","year":"2001","unstructured":"Kobayashi N, Kadono Y, Naito A et al (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20:1271\u20131280","journal-title":"EMBO J"},{"key":"1216_CR26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309\u2013319","journal-title":"Cell"},{"key":"1216_CR27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S8756-3282(99)00162-3","volume":"25","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1999) Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255\u2013259","journal-title":"Bone"},{"key":"1216_CR28","doi-asserted-by":"crossref","first-page":"27307","DOI":"10.1016\/S0021-9258(19)61511-5","volume":"275","author":"Y Abu-Amer","year":"2000","unstructured":"Abu-Amer Y, Erdmann J, Kollias G, Alexopoulou L, Ross FP, Teitelbaum SL (2000) Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275:27307\u201327310","journal-title":"J Biol Chem"},{"key":"1216_CR29","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-\u03b1 induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481\u20131488","journal-title":"J Clin Invest"},{"key":"1216_CR30","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1359\/jbmr.2001.16.9.1593","volume":"16","author":"K Kaji","year":"2001","unstructured":"Kaji K, Katogi R, Azuma Y, Naito A, Inoue JI, Kudo A (2001) Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Miner Res 16:1593\u20131599","journal-title":"J Bone Miner Res"},{"key":"1216_CR31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jcb.1202","volume":"83","author":"W Zou","year":"2001","unstructured":"Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit X (2001) Tumor necrosis factor-a mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 83:70\u201383","journal-title":"J Cell Biochem"},{"key":"1216_CR32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbrc.2007.04.058","volume":"357","author":"A Nakao","year":"2007","unstructured":"Nakao A, Fukushima H, Kajiya H, Ozeki S, Okabe K (2007) RANKL-stimulated TNFa production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways. Biochem Biophys Res Commun 357:945\u2013950","journal-title":"Biochem Biophys Res Commun"},{"key":"1216_CR33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI200523394","volume":"115","author":"S Wei","year":"2005","unstructured":"Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282\u2013290","journal-title":"J Clin Invest"},{"key":"1216_CR34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/345442a0","volume":"345","author":"H Yoshida","year":"1990","unstructured":"Yoshida H, Hayashi S, Kunisada T et al (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442\u2013444","journal-title":"Nature"},{"key":"1216_CR35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"1216_CR36","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI200316924","volume":"111","author":"R Faccio","year":"2003","unstructured":"Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL (2003) c-Fms and the \u03b1v\u03b23 integrin collaborate during osteoclast differentiation. J Clin Invest 111:749\u2013758","journal-title":"J Clin Invest"},{"key":"1216_CR37","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/en.140.9.4367","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367\u20134370","journal-title":"Endocrinology"},{"key":"1216_CR38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0531-5565(03)00069-X","volume":"38","author":"BR Troen","year":"2003","unstructured":"Troen BR (2003) Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 38:605\u2013614","journal-title":"Exp Gerontol"},{"key":"1216_CR39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1359\/jbmr.2003.18.4.599","volume":"18","author":"M Zaidi","year":"2003","unstructured":"Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL (2003) Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 18:599\u2013609","journal-title":"J Bone Miner Res"},{"key":"1216_CR40","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI118984","volume":"98","author":"D Lajeunesse","year":"1996","unstructured":"Lajeunesse D, Busque L, Menard P, Brunette MG, Bonny Y (1996) Demonstration of an osteoblast defect in two cases of human malignant osteopetrosis. Correction of the phenotype after bone marrow transplant. J Clin Invest 98:1835\u20131842","journal-title":"J Clin Invest"},{"key":"1216_CR41","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","volume":"15","author":"FH Glorieux","year":"2000","unstructured":"Glorieux FH, Rauch F, Plotkin H et al (2000) Type v osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 15:1650\u20131658","journal-title":"J Bone Miner Res"},{"key":"1216_CR42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type vi: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:30\u201338","journal-title":"J Bone Miner Res"},{"key":"1216_CR43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S8756-3282(02)00808-6","volume":"31","author":"M Labuda","year":"2002","unstructured":"Labuda M, Morissette J, Ward LM et al (2002) Osteogenesis imperfecta type vii maps to the short arm of chromosome 3. Bone 31:19\u201325","journal-title":"Bone"},{"key":"1216_CR44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","volume":"31","author":"LM Ward","year":"2002","unstructured":"Ward LM, Rauch F, Travers R et al (2002) Osteogenesis imperfecta type vii: an autosomal recessive form of brittle bone disease. Bone 31:12\u201318","journal-title":"Bone"},{"key":"1216_CR45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/00004770-200311000-00009","volume":"29","author":"IB Bender","year":"2003","unstructured":"Bender IB (2003) Paget's disease. J Endod 29:720\u2013723","journal-title":"J Endod"},{"key":"1216_CR46","unstructured":"Siris ES, Roodman GD (2003) Paget\u2019s disease. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Chicago, pp 495\u2013508"},{"key":"1216_CR47","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI9133","volume":"105","author":"C Menaa","year":"2000","unstructured":"Menaa C, Reddy SV, Kurihara N et al (2000) Enhanced rank ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 105:1833\u20131888","journal-title":"J Clin Invest"},{"key":"1216_CR48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S8756-3282(00)00345-8","volume":"27","author":"SD Neale","year":"2000","unstructured":"Neale SD, Smith R, Wass JA, Athanasou NA (2000) Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin d(3) and RANKL. Bone 27:409\u2013416","journal-title":"Bone"},{"key":"1216_CR49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1258\/000456302760413324","volume":"39","author":"KA Buckley","year":"2002","unstructured":"Buckley KA, Fraser WD (2002) Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses\/potential therapeutic agents and biochemical markers. Ann Clin Biochem 39:551\u2013556","journal-title":"Ann Clin Biochem"},{"key":"1216_CR50","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1172\/JCI116422","volume":"91","author":"M Sahni","year":"1993","unstructured":"Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004\u20132011","journal-title":"J Clin Invest"},{"key":"1216_CR51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/8756-3282(95)00426-2","volume":"18","author":"M Nishikawa","year":"1996","unstructured":"Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N (1996) Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9\u201314","journal-title":"Bone"},{"key":"1216_CR52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jbmr.5650140212","volume":"2","author":"RG Russell","year":"1999","unstructured":"Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA (1999) The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 2:53\u201365","journal-title":"J Bone Miner Res"},{"key":"1216_CR53","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","volume":"291","author":"V Viereck","year":"2002","unstructured":"Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680\u2013686","journal-title":"Biochem Biophys Res Commun"},{"key":"1216_CR54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","volume":"19","author":"B Pan","year":"2004","unstructured":"Pan B, Farrugia AN, To LB, FindlayDM GJ, Lynch K, Zannettino AC (2004) The nitrogen containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19:147\u2013154","journal-title":"J Bone Miner Res"},{"key":"1216_CR55","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s11999-008-0409-y","volume":"467","author":"HK Kim","year":"2009","unstructured":"Kim HK, Kim JH, Abbas AA, Yoon TR (2009) Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res 467:3121\u20133128","journal-title":"Clin Orthop Relat Res"},{"key":"1216_CR56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/147323000903700216","volume":"37","author":"Y Xiong","year":"2009","unstructured":"Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD (2009) Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 37:407\u2013416","journal-title":"J Int Med Res"},{"key":"1216_CR57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bone.2003.08.013","volume":"34","author":"B Pan","year":"2004","unstructured":"Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, Evdokiou A, Lynch K, Atkins GJ, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 34:112\u2013123","journal-title":"Bone"},{"key":"1216_CR58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00223-008-9104-y","volume":"82","author":"AI Idris","year":"2008","unstructured":"Idris AI, Rojas J, Greig IR, van't Hof RJ, Ralston SH (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191\u2013201","journal-title":"Calcif Tissue Int"},{"key":"1216_CR59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jcb.21983","volume":"106","author":"IR Orriss","year":"2009","unstructured":"Orriss IR, Key ML, Colston KW, Arnett TR (2009) Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106:109\u2013118","journal-title":"J Cell Biochem"},{"key":"1216_CR60","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","volume":"15","author":"S Pozzi","year":"2009","unstructured":"Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, Schoonmaker J, Xie W, Hideshima T, Weller E, Bouxsein ML, Munshi NC, Anderson KC, Raje N (2009) High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 15:5829\u20135839","journal-title":"Clin Cancer Res"},{"key":"1216_CR61","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/jbm.a.30950","volume":"80","author":"S Greiner","year":"2007","unstructured":"Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B (2007) The effect of zoledronic acid incorporated in a poly(D, L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 80:769\u2013775","journal-title":"J Biomed Mater Res A"},{"key":"1216_CR62","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1742-7843.2005.pto_176.x","volume":"97","author":"M Kellinsalmi","year":"2005","unstructured":"Kellinsalmi M, Monkkonen H, Monkkonen J, Leskela HV, Parikka V, Hamalainen M, Lehenkari P (2005) In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 97:382\u2013391","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1216_CR63","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1357-2725(01)00147-9","volume":"34","author":"CE Evans","year":"2002","unstructured":"Evans CE (2002) Bisphosphonates modulate the effect of macrophage-like cells on osteoblast. Int J Biochem Cell Biol 34:554\u2013563","journal-title":"Int J Biochem Cell Biol"},{"key":"1216_CR64","first-page":"6001","volume":"60","author":"GG Rehinolz","year":"2000","unstructured":"Rehinolz GG, Getz B, Pederson L et al (2000) Bisphosphonates directly regulate cell proliferation, differentiation and gene expression in human osteoblasts. Cancer Res 60:6001\u20136007","journal-title":"Cancer Res"},{"key":"1216_CR65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/030097498441155","volume":"27","author":"N Giuliani","year":"1998","unstructured":"Giuliani N, Pedrazzoni M, Passeri G, Girasole G (1998) Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 27:38\u201341","journal-title":"Scand J Rheumatol"},{"key":"1216_CR66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2003.08.011","volume":"477","author":"F Itoh","year":"2003","unstructured":"Itoh F, Aoyagi S, Furihata-Komatsu H, Aoki M, Kusama H, Kojima M, Kogo H (2003) Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol 477:9\u201316","journal-title":"Eur J Pharmacol"},{"key":"1216_CR67","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s004419900165","volume":"302","author":"P D\u2019Aoust","year":"2000","unstructured":"D\u2019Aoust P, McCulloch CA, Tenenbaum HC, Lekic PC (2000) Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res 302:353\u2013363","journal-title":"Cell Tissue Res"},{"key":"1216_CR68","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10067-005-1100-2","volume":"24","author":"A Corrado","year":"2005","unstructured":"Corrado A, Cantatore FP, Grano M, Colucci S (2005) Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol 24:527\u2013534","journal-title":"Clin Rheumatol"},{"key":"1216_CR69","first-page":"873","volume":"28","author":"A Corrado","year":"2010","unstructured":"Corrado A, Neve A, Maruotti N, Gaudio A, Marucci A, Cantatore FP (2010) Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Clin Exp Rheumatol 28:873\u2013879","journal-title":"Clin Exp Rheumatol"},{"key":"1216_CR70","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","volume":"104","author":"LI Plotkin","year":"1999","unstructured":"Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363\u20131374","journal-title":"J Clin Invest"},{"key":"1216_CR71","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1067\/mlc.2000.109757","volume":"136","author":"Y Abe","year":"2000","unstructured":"Abe Y, Kawakami A, Nakashima T et al (2000) Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J Lab Clin Med 136:344\u2013354","journal-title":"J Lab Clin Med"},{"key":"1216_CR72","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1359\/jbmr.080617","volume":"23","author":"LI Plotkin","year":"2008","unstructured":"Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T (2008) Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 23:1712\u20131721","journal-title":"J Bone Miner Res"},{"key":"1216_CR73","doi-asserted-by":"crossref","first-page":"8648","DOI":"10.1074\/jbc.M108625200","volume":"277","author":"LI Plotkin","year":"2002","unstructured":"Plotkin LI, Manolagas SC, Bellido T (2002) Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 277:8648\u20138657","journal-title":"J Biol Chem"},{"key":"1216_CR74","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.lfs.2004.04.048","volume":"75","author":"G Kogianni","year":"2004","unstructured":"Kogianni G, Mann V, Ebetino F, Nuttall M, Nijweide P, Simpson H, Noble B (2004) Fas\/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci 75:2879\u20132895","journal-title":"Life Sci"},{"key":"1216_CR75","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1067\/mlc.2000.109757","volume":"136","author":"Y Abe","year":"2000","unstructured":"Abe Y, Kawakami A, Nakashima T, Ejima E, Fujiyama K, Kiriyama T, Ide A, Sera N, Usa T, Tominaga T, Ashizawa K, Yokoyama N, Eguchi K (2000) Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J Lab Clin Med 136:344\u2013354","journal-title":"J Lab Clin Med"},{"key":"1216_CR76","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejphar.2008.10.031","volume":"600","author":"MV Gangoiti","year":"2008","unstructured":"Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD (2008) Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol 600:140\u2013147","journal-title":"Eur J Pharmacol"},{"key":"1216_CR77","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/pr8005606","volume":"8","author":"N Bivi","year":"2009","unstructured":"Bivi N, Bereszczak JZ, Romanello M, Zeef LA, Delneri D, Quadrifoglio F, Moro L, Brancia FL, Tell G (2009) Transcriptome and proteome analysis of osteocytes treated with nitrogen-containing bisphosphonates. J Proteome Res 8:1131\u20131142","journal-title":"J Proteome Res"},{"key":"1216_CR78","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","volume":"49","author":"T Bellido","year":"2011","unstructured":"Bellido T, Plotkin LI (2011) Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 49:50\u201355","journal-title":"Bone"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1216-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-012-1216-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1216-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T05:54:16Z","timestamp":1640670856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-012-1216-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,9]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1007\/s00228-012-1216-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,9]]}}}